Navigation Links
AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited
Date:12/5/2011

VIENNA, December 5, 2011 /PRNewswire/ --

AFFiRiS AG announced today that Ali Alloueche is taking senior responsibility for their expanding business development activities. This new management position has been established as a result of the growing development pipeline of the Viennese biopharmaceutical company. As a member of the management team, Ali Alloueche will strategically and operationally support the development of AFFiRiS AG. Before joining AFFiRiS, Ali Alloueche was Head of External R&D at the leading vaccine manufacturer GlaxoSmithKline Biologicals, Belgium.

AFFiRiS AG has appointed Ali Alloueche as Chief Business Officer. In this position he will oversee business activities, strategic alliances and partnerships arising from the continuously growing pipeline of the Viennese biopharmaceutical company. Based on strong IP-positions and its AFFITOME©-technology, AFFiRiS has a diversified pipeline with four vaccine candidates currently in clinical phases and other attractive candidates in pre-clinical stage. Target indications include Alzheimer's, Parkinson's, Atherosclerosis and Hypertension - all diseases with unmet medical needs and attractive market potential.

Prior to joining AFFiRiS Ali Alloueche was Head External R&D at GlaxoSmithKline Biologicals in Belgium. In this position he expanded the company's R&D pipeline and extended its network of collaborators and business partners. In this role, he identified AFFiRiS's Alzheimer's vaccine candidates for GlaxoSmithKline - an activity in 2007 that culminated in a up to EUR 430 million-deal between both companies in October 2008. Prior to GlaxoSmithKline, Ali Alloueche was Research Director at Novartis Vaccines and Diagnostics in Italy and Head Translational Medicine and Scientific Affairs. Commenting on his new position, Ali Alloueche says: "AFFiRiS is one of the most dynamic biopharmaceutical companies in Europe. The company's focus on clinical programs and its robust financial position offer great business opportunities. I am excited about the opportunity to contribute to the further success of AFFiRiS at this particular stage of the company's development."

"Our growing development-pipeline creates more and more business opportunities," comments Walter Schmidt, co-founder and CEO of AFFiRiS, "Together with Ali we will exploit these opportunities further and add to our successful track record of business alliances. The experience he has gained in senior positions at two top ten pharmaceutical companies is a valuable addition to AFFiRiS's in-house expertise."

About AFFiRiS AG (date December 2011):

On the basis of the company's own patent positions AFFiRiS develops tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, Hypertension and several other conditions with unmet medical need and attractive market sizes. Alzheimer's is the current lead indication. For the Alzheimer's vaccine program, a license and option agreement with GlaxoSmithKline was closed in October 2008, triggering an upfront payment of EUR 22.5 million. The contract envisages (milestone-dependent) payments of up to EUR 430 million. A first milestone payment of EUR 10 million was made in October 2009 followed by EUR 3.5 million as announced recently. AFFiRiS currently employs 82 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria (http://www.affiris.com).

Contact AFFiRiS AG:
Julia Bock
Karl-Farkas-Gasse 22
1030 Vienna, Austria
T +43/(0)1/798-15-75-303
E  julia.bock@affiris.com  
W http://www.affiris.com


Editing & Distribution:
PR&D - Public Relations for Research & Education
Mariannengasse 8
1090 Vienna, Austria
T +43/(0)1/505-70-44
E contact@prd.at  
W http://www.prd.at



'/>"/>
SOURCE AFFiRiS AG
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
5. AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing
6. AFFiRiS AG: Vaccination Against Hypertension is Development Project No. 4 and has Already Been Awarded an FFG Grant of up to EUR 1.2 Million
7. AFFiRiS AG: Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board
8. Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure
9. Lockheed Martin Invests in Smart Grid Research and Development at Penn State University
10. Burrill & Company Invests in Taiwan Liposome Company
11. University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... DUBLIN , Jan 19, 2017 Research ... Market by Profiling Technology, Biomolecules, Cancer Type, Application - Global Opportunity ... ... Report, forecasts that the global market is projected to reach $15,737 ... of 13% from 2016 to 2022. Omic technologies ...
(Date:1/19/2017)... and HOUSTON , ... ("NX Prenatal") today announced the formation of its ... leading clinicians and industry veterans who enhance the ... as it accelerates development of its novel prenatal ... provide medical, clinical and strategic guidance for the ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets ... has announced the addition of the ... - Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market ... 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... software to leading biopharmaceutical and medical device manufacturers and regulators, is proud to ... CFR Part 11-compliant email client designed to provide product vigilance departments with the ...
Breaking Biology Technology:
(Date:1/12/2017)... DIEGO , Jan. 12, 2017  Trovagene, Inc. ... tumor DNA (ctDNA) technologies, today announced that it has ... Europe and the Middle East ... tests.  This milestone marks the first wave of international ... for urine and blood samples. The initial ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol ... Capital Group, Inc., has been named to the elite "Forbes 30 ...  was one of 600 people in 20 fields nationwide to be ... of the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers ...
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at ... global leader in connected health and biometric measurement devices and services, will ... On display in A&D Medical,s special CES Exhibit Suite ... the ongoing expansion of the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):